- Boston Scientific (BSX +3.7%) trades notably higher in morning action.
- The company has inked a co-promotion agreement with The Medicines Company (MDCO -1.4%) for the Promus PREMIER drug-eluting stent.
- BSX is apparently looking to leverage MDCO's cardio sales force and product portfolio during the U.S. introduction of the new system. (PR)
- In other company news, BSX says retrospective data presented at NANS shows the company's SCS system "provided highly significant pain relief three months after implantation." (PR)